COMPASS Pathways plc (NASDAQ:CMPS) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its position in COMPASS Pathways plc (NASDAQ:CMPS) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,939 shares of the company’s stock after acquiring an additional 4,981 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.18% of COMPASS Pathways worth $971,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC grew its holdings in shares of COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after purchasing an additional 186,040 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of COMPASS Pathways in the third quarter worth $597,000. Armistice Capital LLC purchased a new stake in shares of COMPASS Pathways during the third quarter worth $2,960,000. Vivo Capital LLC purchased a new stake in shares of COMPASS Pathways during the third quarter worth $11,899,000. Finally, AE Wealth Management LLC purchased a new position in COMPASS Pathways in the third quarter valued at $106,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CMPS shares. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Thursday, April 18th. Finally, Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They issued an “overweight” rating and a $30.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $47.40.

COMPASS Pathways Trading Down 1.3 %

NASDAQ:CMPS opened at $8.25 on Wednesday. COMPASS Pathways plc has a 1 year low of $5.01 and a 1 year high of $12.75. The stock has a market cap of $511.01 million, a P/E ratio of -3.45 and a beta of 2.48. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The stock has a 50-day simple moving average of $9.84 and a 200-day simple moving average of $8.40.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). As a group, analysts anticipate that COMPASS Pathways plc will post -2.4 earnings per share for the current fiscal year.

Insider Transactions at COMPASS Pathways

In related news, Director Ekaterina Malievskaia sold 11,862 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $10.06, for a total value of $119,331.72. Following the transaction, the director now directly owns 4,110,338 shares of the company’s stock, valued at approximately $41,350,000.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Ekaterina Malievskaia sold 11,862 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $10.06, for a total value of $119,331.72. Following the completion of the sale, the director now directly owns 4,110,338 shares of the company’s stock, valued at approximately $41,350,000.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George Jay Goldsmith sold 15,740 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total value of $166,529.20. Following the transaction, the director now owns 4,079,107 shares in the company, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,601 shares of company stock worth $1,338,911. 4.25% of the stock is currently owned by insiders.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.